Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer

Catalano, Vincenzo; Loupakis, Fotios; Graziano, Francesco; Bisonni, Renato; Torresi, U.; Vincenzi, Bruno; Mari, D.; Giordani, Paolo; Alessandroni, Paolo; Salvatore, Lisa; Fornaro, Lorenzo; Santini, Daniele; Baldelli, Anna Maria; Rossi, David; Giustini, Lucio; Silva, R.R.; Falcone, Alfredo; Demidio, S.; Rocchi, Marco; Fedeli, Stefano

doi:10.1093/annonc/mdr062

Cited by 97 publications

(110 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with the MA histotype had a worse disease-free survival than AD patients without neo-and adjuvant chemotherapy (86 vs. 161 months, P < 0.001; and 86 vs. 128 months, P < 0.001; respectively); however, when neo-and adjuvant chemotherapy were added, the differences in DFS between MA and AD were not of statistical significance. In agreement with our study [10], a recent analysis suggested that a comparable benefit was derived from adjuvant chemotherapy for both stage II and III MA and AD after radical resection. In contrast, a poor response to chemotherapy was previously demonstrated in MA patients who received palliative chemotherapeutic treatment [24,28,29].…”

Section: Discussionsupporting

confidence: 93%

Mucinous Adenocarcinomas Histotype Can Also be a High-Risk Factor for Stage II Colorectal Cancer Patients

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Colorectal mucinous adenocarcinoma (MA) has been associated with a worse prognosis than adenocarcinoma (AD) in advanced stages. Little is known about the prognostic impact of a mucinous histotype on the early stages of colorectal cancer with negative lymph node (LN) metastasis. In contrast to the established prognostic factors such as T stage and grading, the histological subtype is not thought to contribute to the therapeutic outcome, although different subtypes can potentially represent different entities. In this study, we aimed to define the prognostic value of mucinous histology in colorectal cancer with negative LNs. Methods: Between 2006 and 2017, a total of 4893 consecutive patients without LN metastasis underwent radical surgery for primary colorectal cancer (MA and AD) in Fudan University Shanghai Cancer Center (FUSCC). Clinical, histopathological, and survival data were analyzed. Results: The incidence of MA was 11% in 4893 colorectal cancer patients without LN metastasis. The MA patients had a higher T category, a greater percentage of LN harvested, larger tumor size and worse grading than the AD patients (p < 0.001 for each). We found that MA histology was correlated with a poor prognosis in terms of relapse in node-negative patients, and MA histology combined with TNM staging may be a feasible method for predicting the relapse rate. Additionally, MA presented as a high-risk factor in patients with negative perineural or vascular invasion and well/moderate-differentiation and showed a more dismal prognosis for stage II patients. Meanwhile, the disease-free survival was identical in MA and AD patients after neo- and adjuvant chemotherapy. Conclusion: MA histology is an independent predictor of poor prognosis due to relapse in LN-negative colorectal cancer patients. Mucinous histology can suggest a possible high risk in early-stage colorectal carcinoma.

show abstract

Section: Discussionsupporting

confidence: 93%

Mucinous Adenocarcinomas Histotype Can Also be a High-Risk Factor for Stage II Colorectal Cancer Patients

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…There are 3759 English literatures in original search, after exclusion and screening, 28 English literatures (Cusack et al, 1996;Sun et al, 1996;Wu et al, 1996;Enriquez et al, 1998;Cerottini et al, 1999;Consorti et al, 2000;Nozoe et al, 2000;Kanemitsu et al, 2003;Chen et al, 2004;Du et al, 2004;Papadopoulos et al, 2004;Kang et al, 2005;You et al, 2006;Grillo-Ruggieri et al, 2007;Hill et al, 2007;Lee et al, 2007;Farhat et al, 2008;Pande et al, 2008;Catalano et al, 2009;Min et al, 2009;Song et al, 2009;Xie et al, 2009;Sultan et al, 2010;Catalano et al, 2011;Jivapaisarnpong et al, 2011;Hyngstrom et al, 2012;Langner et al, 2012;Yamaguchi et al, 2012) and 2 Chinese literatures (Songqing et al, 2002;Miao et al, 2005) meet the requirements. In the 30 literatures, 21 literatures can be used for Meta analysis of the relationship of mucinous adenocarcinoma and TNM staging, including 444489 cases, in which mucinous adenocarcinoma were 45050 cases, accounting for 10.1% of all cases; 21 literatures can be used for Meta analysis of relationship of mucinous adenocarcinoma and prognosis, including 450804 cases, in which mucinous adenocarcinoma were 45354 cases, accounting for 10.1% of all cases.…”

Section: The General Results Of Selected Literaturementioning

confidence: 99%

TNM Stages and Prognostic Features of Colorectal and Mucinous Adenocarcinoma Patients: a Meta Analysis

Chen¹,

Tang²,

Xiang³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Aim: The significance of the mucinous adenocarcinoma in TNM staging and prognosis for colorectal tumor patients is still controversial. The aim was to provide a meta-analysis for TNM staging and prognostic features of colorectal tumors. Methods: 30 individual case-control studies were finally included into this meta-analysis, involving a total of 444,489 cancer cases and 45,050 mucinous adenocarcinomas, of relations with TNM staging and prognostic features. Results: Compared to non-mucinous adenocarcinoma patients, the TNM IV stage accounted for a larger percentage of mucinous adenocarcinomas (OR=1.48, 95%CI 1.28-1.71, POR<0.001) and the prognosis was significantly poor (HR=1.06, 95%CI 1.04-1.08, P<0.001). After heterogeneity testing, the results was similar to the holistic approach outcome (HR=1.48, 95%CI 1.35-1.62, P<0.001). Conclusion: Compared to patients with non-mucinous adenocarcinomas, mucinous adenocarcinoma patients with later TNM staging make up a big percentage, and mucinous adenocarcinoma is an independent risk factor for poor prognosis.

show abstract

“…New perspectives are given by gene and protein research [2,22,27,28], evaluation of apoptosis-regulating proteins in the context of tumor progression and response to therapy [29], and analysis of molecular signatures in colorectal cancer [30,31].…”

Section: Discussionmentioning

confidence: 99%

Prognostic Factors Assessed for 15,096 Patients with Colon Cancer in Stages I and II

et al. 2012

View full text Add to dashboard Cite

Despite favorable prognosis and R0 resection, a small percentage of patients will still relapse. The most important risk factor comprising the tumor-free survival is the pT stage followed by L-status and age. These results should be taken into consideration when determining the course for adjuvant chemotherapy, especially if the course includes the recommendation of clinical trial participation for stage II colon cancer patients after an R0 resection.

show abstract

Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer

Abstract: For patients with stage II and III colon cancer who underwent curative surgery, mucinous histology has no significant correlation with prognosis compared with NMC. This retrospective analysis suggests a comparable benefit from adjuvant chemotherapy for MC compared with NMC.

Cited by 97 publications

References 27 publications

Mucinous Adenocarcinomas Histotype Can Also be a High-Risk Factor for Stage II Colorectal Cancer Patients

Mucinous Adenocarcinomas Histotype Can Also be a High-Risk Factor for Stage II Colorectal Cancer Patients

TNM Stages and Prognostic Features of Colorectal and Mucinous Adenocarcinoma Patients: a Meta Analysis

Prognostic Factors Assessed for 15,096 Patients with Colon Cancer in Stages I and II

Contact Info

Product

Resources

About